15:06 EDT OS Therapies (OSTX) CEO Paul Romness sees ‘huge upside potential’
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX:
- OS Therapies Raises $4.2M Through Warrant Exercise
- OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating
- OS Therapies granted End of Phase 2 Meeting by FDA to review OST-HER2 program
- Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress
- OS Therapies reports ‘positive’ results from Phase 2b trial of OST-HER2